Johnson & Johnson Statement on COVID-19 Vaccine (7/12)

Angie Szumlinski
|
July 13, 2021
Image

The company says the safety and well-being of the people who use our products is our number one priority.

Rare cases of the neurological disorder, Guillain-Barré syndrome have been reported following vaccination with the Janssen COVID-19 vaccine. Most occurred within 42 days after vaccination. While the chance of having this occur is very low, Johnson & Johnson has updated its COVID-19 Vaccine Factsheet to include important information about these rare cases and on the signs and symptoms of Guillain-Barré syndrome. Updates with this new information will be implemented in other regions of the world according to local regulatory procedures.

You can read their full statement on their website.


Related Posts

Image showing a coffee cup.
Angie Szumlinski
|
January 31, 2025

Angie’s Weekly Round Up

Image
Angie Szumlinski
|
January 30, 2025

Agency Nursing and Quality